NRC FORM 374									
			U.S. NUCLEAR REGULATORY COMMISSION	Amendment No. 59					
	MATERIALS LICENSE								
Part auth and licer	Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.								
Licensee In accordance with letter dated				4. Expiration Date: July 31, 2021					
1. Barnes-Jewish St. Peter's Hospital			May 06, 2019. EAR REGU						
		Č,	4	5. Docket No.: 030-17414					
2.	10 Hospital Dr. Dept. of Radiology St. Peters, MO 63376	S. A	3. License number: 24-18968-01 is amended in its entirety to read as follows:	Reference No.:					
6.	Byproduct, source, and/or special nuclear material	7. Chemical and/or physical f	orm						
A.	Any byproduct material permitted by 10 CFR 35.100	A. Any O	A. As Needed	 A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. 					
В.	Any byproduct material permitted by 10 CFR 35.200	B. Any	B As Needed	 For use in imaging and localization studies permitted by 10 CFR 35.200. 					
C.	Any byproduct material permitted by 10 CFR 35.300	C. Any	$\begin{array}{c} \textbf{C. 1 curie total} \\ \begin{array}{c} \checkmark \\ \checkmark $	C. For any use permitted by 10 CFR 35.300.					
D.	lodine-125 permitted by 10 CFR 35.400	 D. Sealed Sources (IsoAID Model IAI-125A (Advant I-125); Medi-Physics, In GE Healthcare (formerly Oncura), Model 6711 (OncoSeed); Therageni Corporation, Model I-Se AgX100) 	age c., d/b/a / cs	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.					

NRC FORM 374A		U.S. NUCLEAR REGULATORY COMMISSION		PAGE 2 OF 4 PAGES			
MATERIALS LICENSE		License Number 24-18968-01 Amendment No. 59	Docket or Reference Number 030-17414				
6.	Byproduct, source, 7. Chemical and/or physical form 8. Maximum amount that licensee 9. Authorized use and/or special nuclear may possess at any one time material R under this license						
E.		y 10 CFR 35.400 Corporation TheraSeed, Model procedure permitted by 10 CFR 35.4					
11.	 CONDITIONS 10. A. Licensed material may be used or stored at the licensee's facilities located at Barnes-Jewish St. Peter's Hospital, 10 Hospital Dr., St. Peters, Missouri 63376. B. Licensed material listed in Subitem Nos. 6.D. through 6 E - may be used at the licensee's facilities located at the Outpatient Surgery Center, 100 Entrance Way, St. Peters, Missouri 63376. C. Licensed material listed in Subitem No. 6.C may be used at the licensee's facility located at the Siteman Cancer Center, 150 Entrance Way, St. Peters MO 63376. 11. The Radiation Safety Officer (RSO) for this license is Constance Courtois, M.D. 12. Licensed material shall only be used by, or under the supervision of: 						
	 A. Individuals permitted to work as authorized users, in accordance with 10 CFR 35.13 and 10 CFR 35.14. B. The following individuals are authorized users for the material and medical uses as indicated: 						
	<u>Authorized User(M.D.,D.O.,etc.)</u> Martin B. Ast, M.D. Joelle Biernacki, M.D.		35.200,10 CFR 35.300 (limited to the second se	oral administration of sodium			

MATERIALS LICENSE	License Number 24-18968-01	Docket or Reference Number 030-17414
SUPPLEMENTARY SHEET	Amendment No. 59	
Authorized User(M.D.,D.O.,etc.)	Material and Use	
Meredith Byers, M.D.	10 CFR 35.100,10 C <u>FR 3</u> 5.200	
Ajay Chapa, M.D.	10 CFR 35,100,10 CFR 35,200,1 iodide 1,131 in quantities less tha	0 CFR 35.300 (limited to the oral administration of sodium or equal to 33 millicuries)
Constance Courtois, M.D.		10 CFR 35.300 (limited to the oral administration of sodium
Heather V. Garrett, M.D.	CFR 35.100,10 CFR 35.200,1 iodide I-131 in quantities less that	10 CFR 35:300 (limited to the oral administration of sodium or equal to 33 millicuries)
Punita Gupta, M.D.	iodide I-131 in quantities less that	
Lannis Elese Hall-Daniels, M.D.	10 CFR 35:300,10 CFR 35:400 (limited to iodine-125 and palladium-103)
James Kelly, M.D.	10 CFR 35.100,10 CFR 35.200,1	10 CFR 35.300 (limited to the oral administration of sodium or equal to 33 millicuries)
Paula M. Leiva, M.D.	10 CFR 35.100,10 CFR 35.200,1 iodide I-131 in quantities less tha	10 CFR 35.300 (limited to the oral administration of sodium an or equal to 33 millicuries)
Michael Penney, M.D.	10 CFR 35,100,10 CFR 35,200	S. S.
Hui Hua Shu, M.D.	10 CFR 35.100,10 CFR 35.200	
Robert Stachecki, M.D.	10 CFR 35.100,10 CFR 35.200,1 iodide 1131 in quantities less tha	10 CFR 35.300 (limited to the oral administration of sodium an or equal to 33 millicuries)
Diana L. Westerfield, D. O.	10 CFR 35:200	Z

NRC	NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 4 OF 4 PAGES				
MATERIALS LICENSE SUPPLEMENTARY SHEET		License Number 24-18968-01	Docket or Reference Number 030-17414		
		Amendment No. 59			
13.	 13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations. A. Application dated February 21, 2011 (ML10600772) B. Letter dated Active 29, 2012 (ML12331A082) C. Letter dated April 23, 2015 (ML15135A399) D. Letter dated July 23, 2015 (ML15210A846) E. Letter dated July 23, 2015 (ML15257A442) F. Letter dated July 23, 2016 (ML16013A241) H. Letter dated January 8, 2016 (ML16013A241) H. Letter dated June 29, 2016 (ML16113A397) J. Letter dated May 6, 2019 (ML19134A331) K. Letter dated July 19, 2019 (ML19217A103) 				
Da	nte:AUG 1 2 2019		FOR THE U.S. NUCLEAR REGULATORY COMMISSION By: Cassandra F. Frazier Region III		